Target Name: FECH
NCBI ID: G2235
Review Report on FECH Target / Biomarker Content of Review Report on FECH Target / Biomarker
FECH
Other Name(s): Ferrochelatase, mitochondrial [Precursor] | Ferrochelatase, mitochondrial (isoform b) | Heme synthetase | HEMH_HUMAN | EPP1 | FECH variant 2 | heme synthase | Ferrochelatase, mitochondrial | ferrochelatase | protoheme ferro-lyase | FECH variant 1 | heme synthetase | Ferrochelatase, transcript variant 1 | Ferrochelatase, mitochondrial (isoform a) | Iron chelatase | Ferrochelatase, transcript variant 2 | protoporphyria | Protoheme ferro-lyase | Heme synthase | FCE | EPP

A Promising Drug Target: Ferrochelatase (FEC) as a Potential Therapy for Mitochondrial Disorders

Mitochondrial disorders are a group of genetic and metabolic disorders caused by defects in the mitochondria, which are the energy-producing structures within cells. These disorders can lead to a range of symptoms, including fatigue, muscle weakness, cognitive impairments, and chronic pain. Despite the increasing understanding of the underlying mechanisms of these disorders, there are currently few effective treatments available. The search for new treatments has led to the exploration of various potential drug targets, including Ferrochelatase (FEC), a protein involved in the mitochondrial function that has been identified as a potential therapeutic target.

Ferrochelatase (FEC)

Ferrochelatase is a protein that is expressed in the mitochondria and is involved in the structure and function of the mitochondria. It is a subunit of the Mitochondrial FAT/DNAJ-binding protein (Mitofusin), which is responsible for the regulation of mitochondrial fusion and fusion-dependent processes. Ferrochelatase plays a crucial role in the regulation of mitochondrial dynamics, including the dynamics of mitochondrial fusion and the dynamics of mitochondrial morphology.

Mitochondrial disorders are a group of genetic and metabolic disorders caused by defects in the mitochondria.

Ferrochelatase is a protein that is expressed in the mitochondria and is involved in the structure and function of the mitochondria.

Ferrochelatase plays a crucial role in the regulation of mitochondrial dynamics, including the dynamics of mitochondrial fusion and the dynamics of mitochondrial morphology.

The Importance of Ferrochelatase in Mitochondrial Disorders

Ferrochelatase is a key protein that is involved in the regulation of the mitochondrial dynamics, including the dynamics of mitochondrial fusion and the dynamics of mitochondrial morphology. The defect in Ferrochelatase has been implicated in the development of various mitochondrial disorders.

Mitochondrial disorders are a group of genetic and metabolic disorders caused by defects in the mitochondria.

Mitochondrial disorders are a group of genetic and metabolic disorders caused by defects in the mitochondria.

Mitochondrial disorders can cause a range of symptoms, including fatigue, muscle weakness, cognitive impairments, and chronic pain.

Despite the increasing understanding of the underlying mechanisms of these disorders, there are currently few effective treatments available.

The search for new treatments has led to the exploration of various potential drug targets, including Ferrochelatase.

Ferrochelatase as a Potential Drug Target

Ferrochelatase has been identified as a potential drug target for the treatment of mitochondrial disorders due to its involvement in the regulation of mitochondrial dynamics. The dysfunction in Ferrochelatase has been implicated in the development of various mitochondrial disorders, including mitochondrial encephalomyopathy (MEN), a progressive neurodegenerative disorder that is caused by a deficiency of dystrophin, a protein that helps maintain the mitochondrial structure and function.

MEN is characterized by a progressive accumulation of mitochondrial organelles, including mitochondrial DNA, in the brain, as well as a progressive loss of motor neurons and cognitive impairments. The defect in Ferrochelatase has been implicated in the development and progression of MEN, as well as in the pathogenesis of other mitochondrial disorders.

In addition to its involvement in the regulation of mitochondrial dynamics, Ferrochelatase has also been implicated in the regulation of cellular processes that are critical for the survival of cells, including the regulation of apoptosis (programmed cell death), cell cycle progression, and the regulation of inflammation.

The Potential therapeutic benefits of targeting Ferrochelatase include the potential to improve the function of mitochondria and to protect against the dysfunctional consequences of mitochondrial disorders.

Conclusion

Ferrochelatase is a protein that is involved in the regulation of the mitochondrial dynamics, including the dynamics of mitochondrial fusion and the dynamics of mitochondrial morphology. The defect in Ferrochelatase has been implicated in the development and progression of various mitochondrial disorders, including MEN. The potential therapeutic benefits of targeting Ferrochelatase include the potential to improve the function of mitochondria and to protect against the dysfunctional consequences of mitochondrial disorders. Further research is needed to determine the effectiveness of Ferrochelatase as a potential drug target for the treatment of mitochondrial disorders.

Protein Name: Ferrochelatase

Functions: Catalyzes the ferrous insertion into protoporphyrin IX

The "FECH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FECH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1